MX2020014107A - Uso de liposoma de mitoxantrona para tratar el linfoma no de hodgkin. - Google Patents

Uso de liposoma de mitoxantrona para tratar el linfoma no de hodgkin.

Info

Publication number
MX2020014107A
MX2020014107A MX2020014107A MX2020014107A MX2020014107A MX 2020014107 A MX2020014107 A MX 2020014107A MX 2020014107 A MX2020014107 A MX 2020014107A MX 2020014107 A MX2020014107 A MX 2020014107A MX 2020014107 A MX2020014107 A MX 2020014107A
Authority
MX
Mexico
Prior art keywords
lymphoma
hodgkin
mitoxantrone liposome
cell lymphoma
treating non
Prior art date
Application number
MX2020014107A
Other languages
English (en)
Inventor
Chunlei Li
Yueying Peng
Kun Lou
Yajuan Wang
Yumei Wang
Shan Chen
Zhibin Meng
Jianfei Xue
Jing Yuan
Hongmei Luo
Xuekun Yao
Shixia Wang
Original Assignee
Cspc Zhongqi Pharmaceutical Tech Shijiazhuang Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cspc Zhongqi Pharmaceutical Tech Shijiazhuang Co Ltd filed Critical Cspc Zhongqi Pharmaceutical Tech Shijiazhuang Co Ltd
Publication of MX2020014107A publication Critical patent/MX2020014107A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe el uso de una preparación farmacéutica liposomal de mitoxantrona en la preparación de un medicamento para tratar un linfoma, en donde el linfoma es preferiblemente linfoma no de Hodgkin, además, preferentemente linfoma no de Hodgkin agresivo, más preferentemente linfoma difuso de células B grandes o linfoma periférico de células T, y más preferentemente linfoma difuso de células B grandes en recaída o refractario o linfoma periférico de células T; los liposomas de mitoxantrona se utilizan como un solo agente terapéutico antitumoral sin combinarse con otros agentes antitumorales.
MX2020014107A 2018-07-11 2019-07-10 Uso de liposoma de mitoxantrona para tratar el linfoma no de hodgkin. MX2020014107A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810756315.7A CN110711178A (zh) 2018-07-11 2018-07-11 盐酸米托蒽醌脂质体治疗非霍奇金淋巴瘤的用途
PCT/CN2019/095396 WO2020011189A1 (zh) 2018-07-11 2019-07-10 米托蒽醌脂质体治疗非霍奇金淋巴瘤的用途

Publications (1)

Publication Number Publication Date
MX2020014107A true MX2020014107A (es) 2021-05-27

Family

ID=69143169

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020014107A MX2020014107A (es) 2018-07-11 2019-07-10 Uso de liposoma de mitoxantrona para tratar el linfoma no de hodgkin.

Country Status (16)

Country Link
US (1) US11583508B2 (es)
EP (1) EP3821887B1 (es)
JP (1) JP2021530489A (es)
KR (1) KR20210031695A (es)
CN (2) CN110711178A (es)
AU (1) AU2019301101B2 (es)
BR (1) BR112021000452A8 (es)
CA (1) CA3105698A1 (es)
CU (1) CU20210003A7 (es)
ES (1) ES2980641T3 (es)
FI (1) FI3821887T3 (es)
MX (1) MX2020014107A (es)
PL (1) PL3821887T3 (es)
PT (1) PT3821887T (es)
SG (1) SG11202013236XA (es)
WO (1) WO2020011189A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220140805A (ko) * 2020-02-10 2022-10-18 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 유방암 치료를 위한 미토산트론 염산염 리포솜의 용도
CN115427020A (zh) * 2020-04-13 2022-12-02 石药集团中奇制药技术（石家庄）有限公司 盐酸米托蒽醌脂质体的用途
US20230293454A1 (en) * 2020-08-07 2023-09-21 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd Use of mitoxantrone hydrochloride liposome and pegaspargase
EP4205747A4 (en) * 2020-08-27 2024-08-21 Cspc Zhongqi Pharmaceutical Tech Shijiazhuang Co Ltd USE OF MITOXANTRONE HYDROCHLORIDE AND CYCLOPHOSPHAMIDE LIPOSOME, VINCRISTINE AND PREDNISONE
CN115212168A (zh) * 2021-04-16 2022-10-21 石药集团中奇制药技术（石家庄）有限公司 盐酸米托蒽醌脂质体的用途
EP4349325A1 (en) * 2021-05-28 2024-04-10 CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Use of mitoxantrone hydrochloride liposome in preparation of drugs for treating advanced solid tumors
WO2023036161A1 (zh) * 2021-09-07 2023-03-16 石药集团中奇制药技术（石家庄）有限公司 米托蒽醌脂质体、硼替佐米和地塞米松治疗多发性骨髓瘤的用途
CN117940164A (zh) * 2022-04-26 2024-04-26 石药集团中奇制药技术（石家庄）有限公司 米托蒽醌脂质体联合抗血管生成靶向药治疗卵巢癌的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0303719A2 (hu) * 2000-10-16 2004-03-01 Neopharm, Inc. Mitoxantron hatóanyag-tartalmú liposzómás gyógyszerkészítmények és eljárás az előállításukra
US20040170677A1 (en) * 2002-11-26 2004-09-02 Ning Hu Method of drug loading in liposomes by gradient
EP1537858A1 (en) * 2003-12-04 2005-06-08 Vectron Therapeutics AG Drug delivery vehicles and uses thereof
EP1538164A1 (en) * 2003-12-04 2005-06-08 Vectron Therapeutics AG RGD targeting moiety its production and use
JP4715133B2 (ja) * 2004-08-26 2011-07-06 コニカミノルタエムジー株式会社 抗腫瘍リポソーム製剤およびその製造方法
CN101209243B (zh) * 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
WO2009020590A1 (en) * 2007-08-07 2009-02-12 Celgene Corporation Methods for treating lymphomas in certain patient populations and screening patients for said therapy
CN103622909A (zh) * 2012-08-28 2014-03-12 吉林大学 一种含心磷脂的脂质体新制剂及其在抗肿瘤药物中的应用
CA2883443C (en) * 2012-08-30 2021-01-12 James Sacchettini Compositions and methods for drug-sensitization or inhibition of a cancer cell

Also Published As

Publication number Publication date
CN110711178A (zh) 2020-01-21
SG11202013236XA (en) 2021-02-25
CN112384207B (zh) 2024-02-06
EP3821887A4 (en) 2022-04-20
CA3105698A1 (en) 2020-01-16
AU2019301101B2 (en) 2023-10-05
US11583508B2 (en) 2023-02-21
CU20210003A7 (es) 2021-08-06
CN112384207A (zh) 2021-02-19
FI3821887T3 (fi) 2024-06-04
BR112021000452A2 (pt) 2021-04-06
KR20210031695A (ko) 2021-03-22
PT3821887T (pt) 2024-06-12
EP3821887A1 (en) 2021-05-19
AU2019301101A1 (en) 2021-01-28
ES2980641T3 (es) 2024-10-02
EP3821887B1 (en) 2024-05-15
PL3821887T3 (pl) 2024-07-08
WO2020011189A1 (zh) 2020-01-16
BR112021000452A8 (pt) 2021-11-03
US20210267915A1 (en) 2021-09-02
JP2021530489A (ja) 2021-11-11

Similar Documents

Publication Publication Date Title
MX2020014107A (es) Uso de liposoma de mitoxantrona para tratar el linfoma no de hodgkin.
MX2009002196A (es) Oblea de buprenorfina para terapia de sustitucion de farmacos.
NZ628021A (en) Pharmaceutical composition comprising empagliflozin and antiobesity drug
Ferreri et al. Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma?
NO332893B1 (no) Anvendelse av antistoff for fremstilling av medikament til anvendelse ved CVP-kjemoterapi
NZ543661A (en) Pyrazolo-quinazoline derivatives having antitumor activity and process for their preparation
NZ544472A (en) Compounds and therapeutical use thereof
AR052774A1 (es) Inmunoterapia para trastornos autoinmunes
NZ707377A (en) Combination therapy methods for treating proliferative diseases
PH12019500892A1 (en) Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
EP4389213A3 (en) Treatment of fabry disease in ert-naive and ert-experienced patients
NO993520L (no) Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjon
AR023806A1 (es) Uso de una mezcla de peptidos para la manufactura de un agente terapeutico para la profilaxis y/o el tratamiento del cancer, las composicionesfarmaceuticas y vacunas que contienen dicha mezcla y los procedimientos de preparacion de dichas composiciones y vacunas
MX2018013873A (es) Irinotecan nanoliposomico para usarse en el tratamiento del cancer de pulmon de celulas pequeñas.
PH12020551176A1 (en) Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
WO2018102261A3 (en) Boronic derivatives hydroxamates as anticancer agents
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
NZ580975A (en) Drug combination of beta 2 agonist and a progestin for the treatment of muscle loss
MX2022004739A (es) Compuesto novedoso y composicion farmaceutica para prevencion o tratamiento de cancer que comprende el mismo.
MX2009008813A (es) Composicion farmaceutica que contiene floroglucinol y paracetamol.
TWI799923B (zh) 硫代咪唑烷酮藥物在治療covid-19疾病中的用途
GEP20115158B (en) Use of ivabradine for obtaining medicaments intended for the treatment of endothelial dysfunction
MX2022015438A (es) Formulaciones de tableta dispersable que comprenden dolutegravir.
MX2018008196A (es) Tratamiento para cancer de mama usando una combinacion de una formulacion liposomal cationica de taxano, una formulacion no liposomal de taxano y un agente activo adicional.
MXPA05009849A (es) Terapia combinada que comprende nemorubicina y un inhibidor de la ciclooxigenasa-2.